However, preliminary clinical trial data from our group demonstrate that bintrafusp alfa has significant activity as a monotherapy in patients with HPV-associated malignances, resulting in a median overall survival (OS) of 21.3 months in comparison to OS ≤ 12 months following anti-PD-1/PD-L1 therapy9 (NCT02517398 and NCT03427411). The gene discussed is PDCD1; the disease is cancer.